Eflapegrastim

CHEMBL3833384 Phase 4 Onaylandı Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

This medication stimulates your bone marrow to produce more white blood cells, helping to reduce the risk of serious infections after chemotherapy. It belongs to a class of drugs called colony-stimulating factors.

Terapötik Alanlar

Hematology Oncology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This medication stimulates your bone marrow to produce more white blood cells, helping to reduce the risk of serious infections after chemotherapy. It belongs to a class of drugs called colony-stimulating factors.

Yes, Eflapegrastim is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3833384. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Eflapegrastim PillFYI'da

Hızlı Veriler

Eş Anlamlılar: 1

Dış Bağlantılar

ChEMBL CHEMBL3833384

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.